StockNews.com Initiates Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Equities research analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report issued on Thursday. The brokerage set a “hold” rating on the stock.

A number of other analysts have also recently commented on the stock. Northland Securities restated a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 12th. Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Finally, HC Wainwright lowered their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Monday, August 12th. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.00.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ:ONCT opened at $0.53 on Thursday. Oncternal Therapeutics has a 52-week low of $0.53 and a 52-week high of $13.14. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The stock has a 50 day moving average price of $1.22 and a 200-day moving average price of $4.40.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.